With a pilot study complete, scientists from GATC Biotech subsidiary LifeCodexx have started the clinical validation study of a sequencing-based trisomy 21 test, which it plans to launch by the end of the year.

The company will conduct the clinical validation study on 500 samples in conjunction with several European prenatal centers on the Illumina HiSeq 2000. In a statement, CEO Michael Lutz said the researchers would pool up to seven samples, which would help cut costs by 50 percent.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.